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Despite the great strides made in imaging breast cancer (BC) in
humans, the current imaging modalities miss up to 30% of BC,
do not distinguish malignant lesions from benign ones, and re-
quire histologic examinations for which invasive biopsy must
be performed. Annually in the United States, approximately 5.6
million biopsies find benign lesions. More than 50% of human
BCsoverexpress cyclin D1, and all BCs exhibit VPAC1 oncogene
products. Together, these gene products may provide an excel-
lent biomarker for the early and accurate detection of BC. We
have evaluated 4 biologically active peptide analogs that have
high affinity for VPAC1. The transgenic MMTVneu mice sponta-
neously develop BC and metastatic lesions that overexpress
cyclin D1 and VPAC1 biomarkers. The MMTVneu mouse, there-
fore, provides an excellent animal model that mimics the patho-
genesis of human BC. The objective of this investigation was to
determine the ability of 1 of the peptide analogs, 64Cu-TP3805,
to detect BC in MMTVneu mice using 18F-FDG as a gold stan-
dard. Methods: The transgenic MMTVneu mouse colony was
maintained. Offspring were screened for transgenic status by re-
verse transcriptase polymerase chain reaction (RT-PCR). Nine
mice with visible, palpable, or unknown metastatic lesions
were entered into the protocol. 18F-FDG (6,475 6 1,628 kBq
[175 6 44 mCi]) PET served as a control, followed by a CT scan
and 24–48 h later by PET with 64Cu-TP3805 (4,588 6 962 kBq
[124 6 26 mCi]). RT-PCR on excised tumors determined VPAC1
expression, and histology ascertained the pathology. Results:
Ten tumors were detected by PET. Four tumors were detected
both by 18F-FDG and by 64Cu-TP3805. Additionally, 4 tumors
were imaged with 64Cu-TP3805 only. These 8 tumors overex-
pressed VPAC1 receptors and were malignant by histology.
The 2 remaining tumors were visualized with 18F-FDG only.
These tumors did not express the VPAC1 oncogene product
and had benign histology. The standard uptake value ranged
from 3.1 to 18.3 for 64Cu-TP3805 and 0.9 to 1.4 for 18F-FDG.
Conclusion: 64Cu-TP3805 identified all malignant lesions un-
equivocally that overexpressed the VPAC1 oncogene surface
product. The 2 benign tumors that did not express the VPAC1 re-
ceptor were not imaged. 64Cu-TP3805 promises to have the po-
tential for the early and accurate imaging of primary and
metastatic BC.
Key Words: oncogenic PET; PET of breast cancer; transgenic
MMTVneumousemodel; 64Cu-TP3805; oncogenic vs.metabolic
imaging
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Our interest in targeting gene products for the imaging
of mammary tumors stems from the fact that mammogra-
phy, ultrasonography, CT, and MRI miss up to 30% of
malignant lesions in the human breast (1–10). Furthermore,
any suggestive lesions that are found must be examined by
histology, which requires invasive biopsy. An estimated
37 million mammograms were performed in 2007 in the
United States. Approximately 7 million (20%) of those
mammogram results were abnormal (11). Histologic ana-
lyses found benign pathology in 80% of those biopsy
samples taken from mammograms with abnormal findings
(5.6 million). The challenge has been to develop an imaging
agent that will target a specific, fingerprint biomarker that
will visualize malignant breast lesions early and reliably.
The oncogene product VPAC1, named for vasoactive
intestinal peptide and pituitary adenylate cyclase activating
peptide combined, is overexpressed at the onset of onco-
genesis. Targeting VPAC1 receptors, therefore, provides an
opportunity for the early and accurate imaging of breast
cancer. We have performed extensive preclinical molecular
imaging studies, both ex vivo and in athymic nude mice
bearing human breast cancer xenografts, that offer highly
promising results (12,13). In these studies we have targeted
VPAC1 receptors that are overexpressed on all breast
cancers (14). Approximately 104 VPAC1 receptors are ex-
pressed per malignant cell (15,16). Thus far, however, most
imaging has been performed using those breast cancers that
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were xenografts, experimentally implanted and physically
visible in mice.
Although such tumor imaging is consistent with the
practice for preclinical research, an investigation in a model
system that will resemble the real, clinical situation would
be preferable. Therefore, in this study, we describe an
approach that mimics imaging the onset of breast tumors in
humans. The HER2 transgenic mouse model friend virus
B-type (FVB)/N-Tg(MMTVneu)202Mul/J overexpresses
the murine HER2 protein driven by a mouse mammary
tumor virus (MMTV) promoter (17,18). The female
MMTVneu mice develop focal hyperplastic, dysplastic
mammary tumors as early as 4 mo, with a median of
7 mo. By 1 y of age, 80% of the female mice display
mammary fat-pad tumors (17). Three fourths of the tumors
metastasize to the lung at later stages (17). The MMTVneu
tumors also overexpress the cyclin D1 gene product protein
within the malignant cell and VPAC1 receptor protein
on the cell surfaces. These characteristics render the
MMTVneu transgenic mouse an ideal target for imaging
the onset of breast cancer in a fashion that resembles the
pathogenesis of human breast cancer.
We have developed 4 peptide analogs that display high
affinity for the VPAC1 receptors (12). The peptides are
radiolabeled with 64Cu, a positron-emitting (17.4%) radio-
nuclide with a half-life of 12.7 h (13), via an N2S2 chelating
diaminodibenzylthio group connected to a lysine residue
and separated by a flexible, hydrophilic spacer to avoid
steric hindrance (14,19). Biologic activity of the peptide
was not compromised by the addition of the chelator.
TP3805 has a high affinity for VPAC1 Kd, 3.3 · 1029 M)
and excellent stability in vivo (12). Digital autoradiographic
studies showed 6 times greater 64Cu uptake in human BC
specimens than in the adjacent normal tissues (12). Further-
more, the uptake in human breast tumors grown in athymic
nude mice was high (12).
The purpose of this translational research was to examine
the ability of the 64Cu peptide analogs, specifically 64Cu-
TP3805, to image spontaneously grown, known and un-
known tumors in transgenic MMTVneu mice. 18F-FDG
PET served as a gold standard for molecular imaging.
Quantitative reverse transcriptase polymerase chain reac-
tion (RT-PCR) on excised tumors was performed to confirm
the expression of VPAC1 mRNA. Histology was performed
to ascertain tumor pathology.
MATERIALS AND METHODS
MMTVneu Mice
MMTVneu mice of the FVB strain were previously described
(18). Offspring were screened by PCR for their genetic status.
Twice weekly, animals were examined visually and by gentle
palpation for the presence of tumors. Once a tumor was detected,
the animals (n 5 9) were entered into the study within 1–3 wk.
18F-FDG
18F-FDG was obtained commercially from PETNET Solutions,
and a dose with predetermined quantity was drawn in a sterile,
1-mL tuberculin syringe. A calibrated ionization chamber, CRC-
15 (Capintec), was used for the measurement of radioactivity
before and immediately after administration through a lateral tail
vein of anesthetized mice. PET was performed 1 h later.
Synthesis and Evaluation of TP3805
The synthesis, purification, and characterization of VPAC1 re-
ceptor–specific peptides and their radiolabeling with 64Cu-chloride,
including in vivo stability, were described previously (12). The
pituitary adenylate cyclase activating peptide (PACAP) analog
TP3805 was used in this study. Briefly, the PACAP analog with
a C-terminal diaminodithiol (N2S2) chelator was synthesized (12,13)
on a Wang resin using an ABI 341A peptide synthesizer (Applied
Biosystems). Fmoc-Lys (ivDde)wasfirst introducedat theC terminus
of the peptide, followed by 4-aminobutyric acid (y-Aba). The 39-
amino-acid-long PACAP sequence was then assembled by standard
Fmoc couplingwith thefinal histidyl residue, beinga t-Boc–protected
His(Trt) derivative. The capping t-Boc function was necessary to
ensure that the N-terminal amino group remained protected during
subsequent deprotection and coupling cycles performed at the
g-amino group of the C-terminal lysine. The ivDde group at the
C-terminal lysine was then selectively removed with 2% hydrazine,
followed by the successive additions of di-Fmoc-L-diaminopropionic
acid and S-benzoylthioglycolic acid. The resulting protected diami-
nedithiol (NS-benzoyl)2-containing PACAP peptide was cleaved
from the resin using trifluoroacetic acid (TFA):water:phenol:
thioanisole/ethanedithiol (82.5:5:5:5:2.5) and precipitated with
diethyl ether.
The crude peptide was purified to homogeneity by reversed-
phase high-performance liquid chromatography (HPLC) (Waters;
Millipore) on aVydacC4 column (5mm, 10· 250mm). Themass of
the analog–chelator construct was confirmed by electrospray mass
spectrometry. Following the general synthetic scheme, TP3805 was
prepared, purified, and characterized by American Peptide Co.
Preparation of 64Cu-TP-3805 and Quality Control
64Cu (half-life 5 12.7 h, b1 5 17.4%) was obtained once
a week either from Washington University, MDS-Nordion, or
Trace Laboratories, in 0.1 M HCl. Specific activity (MBq/mL
[mCi/mL]) varied from batch to batch and ranged from 1,073 to
37,000 MBq/mL (29–1,000 mCi/mL). The copper content in 64Cu
fromMDS-Nordion was much greater (1 mg/185 MBq [1 mg/5 mCi])
than that in the 64Cu preparations from Washington University.
Twenty micrograms of each peptide were dispensed in 4 mL of
0.1 M ammonium acetate, pH 6.4, in 5 mL in a clean glass test
tube; 100 mg of SnCl22H20 (in 4 mL of 0.1 M HCl) was added as
a deprotecting agent, followed by 200 mL of 0.2 M glycine, pH
9.1, to 2 mL of 64Cu in 0.1 M HCI, which was vortexed and heated
for 45 min at 90C. The final pH was approximately 7.5.
Analysis was performed using a Rainin HPLC with a reversed-
phase C18 Microbond column (Varian Inc.) eluted with a linear
28-min gradient from 10% acetonitrile in 0.1% aqueous TFA to
90% acetonitrile in aqueous 0.1% TFA. A typical HPLC elution
profile is shown in Figure 1, which indicates nearly quantitative
labeling of a peak at a retention time of 6.7 min. Labeling
efficiency was always greater than 95% of total 64Cu. Depending
on the initial 64Cu activity, specific activity ranged between 7.4
and 37 Gbq/mmol (0.2–1.0 Ci/mmol).
PET/CT
The animal protocol was approved by the Jefferson University
Institutional Animal Care and Use Committee. Animals were kept
GENETIC PET OF BREAST CANCER • Thakur et al. 107
fasting for 4 h before the administration of 18F-FDG (6,475 6
1,628 kBq [175 6 44 mCi]) via a lateral tail vein. 64Cu-TP3805
(4,588 6 962 kBq [124 6 26 mCi]) was administered 24–48 h
after the 18F-FDG study. During imaging, animals were anesthe-
tized with an intraperitoneal injection of a mixture of ketamine,
xylazine, and acetopromazine. Animals were kept warm and not
under anesthesia during the radioactive uptake period. PET was
followed by CT, performed at 1 h after the injection of 18F-FDG.
When the animals were injected with 64Cu-TP3805, CT was
performed first, followed by PET at 4 and 24 h after the injection.
PET was performed using an Inveon microPET scanner
(Siemens Medical Solutions), which was known to have the
highest spatial resolution (1 mm in full width at half maximum)
and sensitivity (.10%) among the commercially available small-
animal PET scanners. The highest spatial resolution and sensitiv-
ity made the scanner capable of detecting even approximately
0.5-mm-sized lesions, despite low uptake. An ordered-subset ex-
pectation maximization 3-dimensional (3D) algorithm with 5
iterations and 8 subsets was used for reconstruction.
CTwas performed using a MicroCAT II CT scanner (ImTek Inc.;
Siemens), yielding reconstructed voxels of 103 · 103 · 103 mm.
A Feldkamp, Davis, and Kress cone-beam algorithm was used for
reconstruction. 3D visualization software provided high-quality
images including surface-rendered and maximum-intensity-projection
images.
Image Processing, Quantification, and Visualization
An Inveon Research Workstation (Siemens) was used for image
processing and analysis. An automatic rigid registration algorithm
with weighted mutual information as a measure of similarity was
used for registering PET and CT datasets. The anatomic location
of the tumor was identified from the registered datasets. Volumes
of interest (VOIs) were created on the tumors, and standardized
uptake values (SUVs) for body weight were obtained. VOIs were
created on the PET images. The PET scanner was calibrated with
known activity to get the SUV for body weight values from the
VOI. Amira (Visage Imaging Inc.) was used for 3D visualization.
PET and CT datasets were registered in Amira using a rigid
registration algorithm with normalized mutual information as the
measure of similarity. Surface rendering was performed using the
threshold pixel value for bone from the CT dataset and the tumor
from the PET dataset to localize the tumor with reference to the
skeleton. More anatomic structures were rendered from CT when
it was not able to localize the tumor with skeleton alone. The
anatomic location of the tumor obtained from the visualization
was used to excise the tissue from the tumor for histopathology
and RT-PCR.
Reverse Transcription and RT-PCR
The goal of RT-PCR was to ascertain that the lesions imaged by
64Cu-TP3805 and by 18F-FDG expressed VPAC1 receptors. The
excised tumor tissue architecture was immediately disrupted by
the addition of Trizol (Invitrogen Life Technologies) in the
presence of 2.3-mm zirconia/silica beads to release the RNA
and then homogenized by rapid agitation using the procedure
recommended by the manufacturer (BioSpec Products). The RNA
was extracted, and the total RNA was then reverse-transcribed
using the predeveloped TaqMan assay reagents (Applied Biosys-
tems) for 1 h. The resulting single-strand cDNA was diluted and
used as a template for the PCR with TaqMan master mix, using
specific primers and probes for VPAC1. RT-PCR was performed
FIGURE 1. HPLC elution profile for 64Cu-TP3805. Radio-
activity (99.7%) was eluted in single peak at retention time
5.53 min. Unbound 64Cu elutes at approximately 4 min.
Diagonal line is percentage solvent gradient. Blue line
indicates peptide ultraviolet elution; peptide mass injected
was too small for ultraviolet detection. Pk # 5 peak number.
FIGURE 2. (A–C) Coronal PET slices of MMTVneu mouse.
(D) Surface-rendered CT/64Cu-TP3805 PET image. (E–G)
Axial slices through dotted yellow line. (H) Tumor histology.
Spontaneously grown, unpalpable, and invisible tumor in
intact MMTV mouse was unequivocally detectable by 64Cu-
TP3805 (B, yellow arrow) but not by 18F-FDG (A). Fusion and
surface-rendered 64Cu-TP3805 images (C and D) depict that
it was lung metastatic lesion. RT-PCR demonstrated VPAC1
oncogene product expression, and histology (H) showed
malignant status of tumor (Rs in leftmost panels indicate
right of mouse).
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using a CFD-3200 DNA Engine Opticon System (Bio-Rad
Laboratories) and the following cycling conditions: 95C for
15 s and 60C for 1 min for 50 cycles. The expression levels of
the VPAC1 mRNAwere determined from the cycle threshold (CT)
values normalized to human glyceraldehyde–phosphate dehydro-
genase and standard curves used for calculation (20).
Histology
Immediately after PET, animals were sacrificed by CO2 in-
halation. Tumors were excised and then placed in 10% formalde-
hyde in phosphate-buffered saline. These were then embedded in
paraffin blocks by the institutional histology core facility. Histo-
logic slides (10 mm thick) were prepared and stained with
hematoxylin and eosin. The slides were then read by an attending
pathologist.
RESULTS
The radiochemical purity of 64Cu-TP3805, as determined
by HPLC, is shown in Figure 1 and was consistent with all
preparations used. The specific activity of these prepara-
tions ranged between 7.4 and 37 Gbq/mmol (0.2 and
1.0 Ci/mmol). In 9 mice studied, a total of 10 tumors were
identified by both probes, 18F-FDG and 64Cu-TP3805. Of
these, 4 were visualized, each with 64Cu-TP3805 and
18F-FDG. An additional 4 tumors were visualized with
64Cu-TP3805 only (Figs. 2 and 3). The 2 remaining tumors
were depicted with 18F-FDG (Fig. 4) only.
Histology and RT-PCR showed (Fig. 5) that all 8 tumors
detected by 64Cu-TP3805 were malignant by histology and
expressed VPAC1 receptors in severalfold greater quantity
than did the normal tissue.
The 2 tumors that were not detectable by 64Cu-TP3805
(Fig. 6) but were visualized with 18F-FDG had benign
histology and did not express VPAC1 receptors in any
greater quantity than did the normal tissue. One benign
mass not detectable by 64Cu-TP3805 (Fig. 6) was a cys-
tadenoma of ductal origin. The SUVs for these 8 malignant
tumors ranged from 3.1 to 18.3 for 64Cu-TP3805 and 0.9 to
1.4 for 18F-FDG (6 tumors).
DISCUSSION
An estimated 37 million mammograms are obtained
annually in the United States (11). Of these, approximately
20% are found to be abnormal and require biopsy for
histologic confirmation of this abnormality. Statistical data
suggest that approximately 80% (5.6 million) of these
histologic examinations find benign pathology. None of
the current imaging modalities distinguishes benign lesions
FIGURE 3. (A and B) Coronal PET slices of MMTVneu
mouse. (C) Surface-rendered CT/64Cu-TP3805 PET image.
Visible large primary tumor (yellow arrow) near lowest left
nipple had intense 64Cu-TP3805 uptake in center of tumor
(B). 18F-FDG uptake (A) in tumor was only faint (SUV, 1; high
18F-FDG uptake is in bladder). Surface-rendered image (C)
depicts anatomic location of tumor (blue arrow). RT-PCR
showed VPAC1 expression. Histology (F) showed malignant
tumor and surrounding necrotic tissue. (D and E) Axial slices
through dotted line.
FIGURE 4. (A–C) Coronal PET slices of MMTVneu mouse.
(D) Surface-rendered CT/64Cu-TP3805 PET image. MMTV
mouse had large visible mass in left eye. There was intense
18F-FDG uptake in lesion (A, yellow arrow) (R represents
animal’s right; lower red spot is 18F-FDG uptake in bladder).
There was no 64Cu-TP3805 uptake in lesion (B–D) except in
liver and spleen (B and C). RT-PCR showed no over-
expression of VPAC1. Histology (lower right, H) showed
lesion was benign cystadenoma of ductal origin. (E–G) Axial
slices through dotted yellow line.
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from malignant tumors. Furthermore, they miss up to 30%
of breast tumors (1–10). A compelling need exists for
a probe that will detect breast cancer early and accurately.
Such a probe could also minimize the need for invasive
biopsy in the future. In turn, a reliable molecular probe
could improve the management of breast cancer, minimize
the number of biopsies, reduce patient trauma, and save
significantly on health-care costs.
An array of new radiopharmaceuticals, contrast agents,
and hybrid equipment is being prepared and investigated to
accomplish this goal. We hypothesized that the VPAC1
oncogene product (which is overexpressed on 100% of
breast cancer cells, regardless of their hormonal status at
the onset of oncogenesis) will serve as a specific biomarker
for the early and accurate detection of breast cancers. Our
probe, TP3805, is an analog of PACAP (12) and has a high
receptor specificity and high affinity for VPAC1. TP3805 is
stable in vivo and when injected in nanomolar to micro-
molar quantities does not induce any adverse effects (Zhang
et al., unpublished data, 2008).
The data presented here demonstrate the ability of
TP3805 to detect known and unknown tumors, grown
spontaneously, that mimic human breast cancer pathophys-
iology. The data also show that TP3805 has the unique
characteristic derived by its biomarker specificity of dis-
tinguishing benign lesions from malignant tumors. If this
ability of 64Cu-TP3805 prevails in human subjects, then in
the future, PET with 64Cu-TP3805 will significantly affect
the management of breast cancer. Cancer is the disease of
molecular cell biology. VPAC1 receptors are overexpressed
at the onset of BC; specifically targeting VPAC1 receptors
provides the early detection of primary and metastatic
lesions (21). However, only human clinical data will verify
the merits and the limitations of 64Cu-TP3805 in the
management of patients with well-differentiated BC, met-
astatic lesions, and ductal carcinoma in situ.
18F-FDG, the most commonly used radiopharmaceutical
in oncologic PET, is a nonspecific agent that reflects on the
metabolic activity of a lesion. It does not have the ability to
identify or characterize lesions by their genomic nature or
FIGURE 5. Composite of RT-PCR
curves and histology of 3 tumors from
3 separate MMTV mice. All 3 tumors
had intense 64Cu-TP3805 uptake.
RT-PCR showed overexpression of
VPAC1 receptors, compared with nor-
mal tissue, and histology revealed
that tumors were malignant. However,
18F-FDG images were normal for all
3 tumors.
FIGURE 6. Composite of RT-PCR
curves and histology of 2 tumors from
2 separate MMTV mice. Upper panel
shows 1 tumor with malignant histology
that overexpressed VPAC1 oncogene
product. This tumor had intense
64Cu-TP3805 uptake but no abnormal
18F-FDG uptake. Tumor in lower panel
was the in eye of MMTV mouse (shown
in Fig. 4). Histology showed it was
cystadenoma of ductal origin and did
not express VPAC1. There was no
uptake of 64Cu-TP3805 in lesion but
18F-FDG uptake was highly abnormal
(Fig. 4).
110 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 51 • No. 1 • January 2010
to target specific biomarkers, expressed as a result of
oncogenesis. This limits the ability of 18F-FDG to distin-
guish benign lesions from malignant ones and also to
identify lesions, even those that are malignant in pathology.
Its specificity for detecting primary BC lesions is only
approximately 70% (9,10) and for metastatic BC lesions is
only approximately 80% (22,23). These characteristics of
18F-FDG are evidenced in this study in which 18F-FDG
missed 4 of 8 malignant tumors and imaged 2 of 2 benign
lesions. None of the other imaging modalities, such as
mammography, ultrasonography, CT, or MRI, has been
shown to stratify benign lesions from malignant ones also.
The need for a molecular imaging probe that will address
these serious issues is compelling (13,24).
CONCLUSION
On the basis of the data presented in this report and those
published previously (12), it is reasonable to conclude that
64Cu-TP3805 has the ability to identify malignant lesions
accurately, eliminate those benign masses that do not
express the specific biomarkers of breast cancer, and likely
contribute to the management of patients with breast
cancer.
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